Sponsor: ECOG-ACRIN Cancer Research Group
Sponsor Study ID: EA7222
Study Title: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
CTO #: 104110
NCT Number: NCT06422806
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Soft Tissue
Study Objectives: To assess whether the combination of doxorubicin and pembrolizumab will improve progression free survival in UPS and related poorly differentiated sarcomas relative to doxorubicin alone.